[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Pennsylvania\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":643},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,208,0,25,[9,56,82,121,144,169,191,216,237,265,298,319,340,364,387,409,434,465,486,509,537,558,575,597,620],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100652664","phase-4-evaluation-of-filler-injection-for-chin-profile-enhancement-100652664",false,"NCT07777926","Evaluation of Filler Injection for Chin Profile Enhancement","3-Dimensional Volumetric Analysis of a Hyaluronic Filler Injection for Chin Profile Enhancement","Inclusion Criteria:\n\n* Age 22-55\n* Patients interested in chin profile enhancement.\n* Participants must sign the informed consent form.\n\nExclusion Criteria:\n\n* Prior filler for facial contouring\n* Filler injection within the past 12 months or during duration of study\n* Prior facial cosmetic surgery (i.e.. facelift)\n* Prior facial trauma (i.e.. orbital fracture)\n* Pregnant or breastfeeding at the time of injection (initial visit)\n* Planned dental work within next 2 weeks\n* The following contraindications: patients with known hypersensitivity or severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies, gram-positive bacterial protein allergies, lidocaine allergies or other local anesthetics of the amide type\n* Patients with known bleeding disorders",true,"ALL","22 Years","55 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days.\n\nThe primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. The secondary aim is to collect patient related outcomes (PROs) via FACE-Q.\n\nParticipants will receive hyaluronic acid filler injections (Restylane Lyft(for contouring of the chin. Each patient will receive FDA approved dosages of filler to the lower face region to treat chin regression or chin contouring, as per FDA approved indications.\n\nPrior to injections patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 moths for re-imaging.",[29,30,31],"Chin Regression","Chin Asymmetry","Jawline Contour Deficit",[33,34,35,36,37,38,39,40,41,42],"jaw","Hyaluronic Acid","HA filler","Hyaluronic Acid filler","Filler","Cosmetic","face","dermal filler","chin","jawline","RECRUITING","2026-08-18",{"date":46,"type":47},"2026-08-20","ACTUAL",{"date":49,"type":23},"2026-09-30",{"date":51,"type":23},"2026-12-01",{"name":53,"class":54},"University of Pennsylvania","OTHER",1,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":55},"100625557","phase-2-t4t3-therapy-in-hypothyroidism-100625557","NCT07424183","T4\u002FT3 Therapy in Hypothyroidism","Inclusion Criteria:\n\n1. Male or female, aged 18-70 years\n2. Hypothyroidism due to either thyroid failure or total thyroidectomy for structural thyroid disease (nodules, benign goiter, or thyroid cancer) for at least 6 months\n3. Taking 75-150 mcg per day LT4 and a minimum of 1.2 mcg\u002Fkg\u002Fday, with stable dose of LT4 for at least 3 months prior to enrollment\n4. TSH of 0.5 to 4.0 mU\u002FL within 2 months of enrollment\n5. Persistent symptoms for at least 2 months, and a TSQ score of ≥ 5\n6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study intervention.\n\nExclusion Criteria:\n\n1. Current use of LT3, thyroid extracts, Tirosint liquid or capsules, amiodarone, lithium, methimazole, propylthiouracil, supraphysiologic doses of corticosteroids, immunotherapy, tyrosine kinase inhibitors, interferon, or biotin supplements\n2. Diseases of the pituitary or hypothalamus\n3. History of thyroid cancer requiring suppression of TSH secretion\n4. Unstable cardiac conditions, including uncontrolled hypertension (current blood pressure greater than 160\u002F100), arrhythmia, or angina\n5. Uncontrolled psychiatric disorders\n6. Pregnancy or lactation, or planned pregnancy within the next 7 months\n7. History of food dye allergies\n8. GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2\n9. Other conditions which, in the opinion of the investigators, would prevent them from participating in the full duration of the study (for example, end-stage cancer)","18 Years","70 Years",{"count":65,"type":23},60,[67],"PHASE2","This study will test whether 6 months of combination therapy with levothyroxine (LT4) plus liothyronine (LT3) is superior to LT4 plus placebo in participants with hypothyroidism who have residual symptoms of hypothyroidism with TSH levels within the reference range.",[70],"Hypothyroidism Primary",[72,73,74],"Hypothyroidism","levothyroxine","liothyronine","NOT_YET_RECRUITING",{"date":46,"type":47},{"date":78,"type":23},"2026-11",{"date":80,"type":23},"2027-11",{"name":53,"class":54},{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100398952","phase-3-abatacept-for-the-treatment-of-giant-cell-arteritis-100398952","NCT04474847","Abatacept for the Treatment of Giant Cell Arteritis","A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)","Inclusion Criteria:\n\n1. A diagnosis of newly diagnosed or relapsing GCA. Diagnostic criteria for GCA\n\n   A patient will be said to have GCA by meeting 3 of 5 of the following modified ACR criteria for the classification of GCA in which 1 of the 3 must consist of criteria 4 or 5:\n   1. Age at disease onset ≥ 50 years.\n   2. New onset or new type of localized pain in the head.\n   3. ESR of \\> 40 mm in the first hour by the Westergren method or CRP measurement above the laboratory normal limit.\n   4. Temporal artery abnormality (i.e., temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries).\n   5. Temporal artery or large vessel biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cell or an abnormal temporal artery ultrasound showing features consistent with active giant cell arteritis (\"halo sign\") or characteristic changes of large vessel stenosis or aneurysm by arteriography.\n2. GCA with evidence of active disease (defined below) present within the past 8 weeks.\n3. They must be willing and able to comply with treatment and follow-up procedures.\n4. Both women and men who are of child-bearing potential must be willing to use an effective means of birth control while receiving treatment through this study. Effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or hormonal contraception.\n5. They must be willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Evidence of a recent acute infection defined as:\n\n   * Any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics.\n   * Any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy.\n2. Patients with history of chronic or recurrent bacterial infection (such as chronic pyelonephritis, osteomyelitis, and bronchiectasis etc.).\n3. Patients with a history of recurrent herpes zoster (more than 1 episode) or disseminated (more than 1 dermatome) herpes zoster or disseminated herpes simplex, or ophthalmic zoster. Symptoms of herpes zoster or herpes simplex must have resolved more than 60 days prior to screening.\n4. Patients with a history of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis).\n5. Patients with a history of primary immunodeficiency.\n6. Patients at risk for tuberculosis (TB) defined as follows:\n\n   * Current clinical, radiographic or laboratory evidence of active TB, even if currently being treated. Chest x-rays (posterior\u002Fanterior and lateral) obtained within the 6 months prior to screening and TB testing (IFN-gamma release assay or PPD) performed in the past month prior to screening will be accepted; however, a copy of the reports must be placed in the participant binder.\n   * A history of active TB unless there is documentation that the patient had received prior anti-TB treatment that was appropriate in duration and type according to local health authority guidelines.\n   * Patients with a positive TB screening test indicative of latent TB will not be eligible for the study unless they:\n\n     i. Have no evidence of current TB based on chest x-ray performed during the screening period and by history and physical exam, and ii. They are currently being treated for latent TB or the site has documentation of successful prior treatment of latent TB. Treatment regimens should be dictated by local guidelines as long as the treatment dose and duration meet or exceed local health authority guidelines. If permitted by local guidelines regarding treatment with biologic medications, patients with latent TB may be randomized prior to completion of treatment as long as they have completed at least 4 weeks of treatment and they have no evidence of current TB on chest x-ray at screening.\n7. Patients who are pregnant or who are nursing infants.\n8. Inability to comply with study guidelines.\n9. Cytopenia: platelet count \\\u003C80,000\u002Fmm3, total White Blood Count (WBC) \\\u003C 3,000\u002Fmm3 (3 x 109\u002FL) absolute neutrophil \\\u003C1500\u002Fmm3, hematocrit \\\u003C 20%.\n10. Renal insufficiency defined by a creatinine clearance of less than or equal to 20 ml\u002Fmin.\n11. AST or ALT \\> 3 times above normal laboratory range.\n12. Other severe, progressive, or uncontrolled disease that in the investigator's opinion could prevent a patient from fulfilling the study requirements or that would increase the risk of study participation.\n13. Patients who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Patients who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.\n14. Receipt of an investigational agent or device within 30 days prior to enrollment.\n15. A live vaccination within 3 months before randomization.\n16. Patients on non-biologic immunosuppressants must discontinue these medications before randomization (azathioprine, mycophenolate mofetil, mycophenolic acid, leflunomide, hydroxychloroquine, cyclosporin, tacrolimus, or other conventional immunosuppressive agent).\n17. Patients who had received an alkylating agent such as cyclophosphamide must discontinue these medications at least 8 weeks before randomization.\n18. Patients who have been treated within 4 weeks of randomization with etanercept or within 8 weeks with adalimumab, certolizumab, golimumab, or infliximab.\n19. Patients who have been treated within 8 weeks of randomization with anti-IL-6 agents (e.g., tocilizumab, sirukumab) or a janus kinase inhibitor.\n20. Patients who have been treated within 4 weeks of randomization with anakinra.\n21. Patients who have received prior treatment with rituximab within the past 6 months prior to randomization.\n22. Patients who have received prior treatment with abatacept or CTLA4-Ig.\n23. Patients who will require oral or IV glucocorticoid treatment during the trial for conditions other than GCA.\n24. Hypersensitivity to abatacept and\u002For its excipients.\n25. Presence of any of the following disease processes:\n\n    * Takayasu arteritis\n    * Granulomatosis with polyangiitis\n    * Microscopic polyangiitis\n    * Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\n    * Polyarteritis nodosa\n    * Cogan's syndrome\n    * Behçet's disease\n    * Sarcoidosis\n    * Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics vasculitis\n    * Cryoglobulinemic vasculitis\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Mixed connective tissue disease or any overlap autoimmune syndrome","50 Years",{"count":91,"type":23},78,[93],"PHASE3","This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg\u002Fweek or placebo. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept\u002Fplacebo will be stopped.\n\nPatients who do not achieve remission by Month 3, who experience a relapse within the first 12 months will have the option of receiving open-label abatacept for a maximum of 12 months.",[96],"Giant Cell Arteritis",[98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113],"Vasculitis","Arteritis","Temporal Arteritis","Abatacept","CTLA4-Ig","Autoimmune Diseases","Immune System Diseases","Immunosuppressive agent","Prednisone","Glucocorticoids","Corticosteroids","Treatment","Pharmacologic Actions","Therapeutic Uses","Anti Inflammatory Agents","Antirheumatic Agents",{"date":46,"type":47},{"date":116,"type":47},"2021-03-29",{"date":118,"type":23},"2029-12",{"name":53,"class":54},10,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100281139","phase-2-a-randomized-multicenter-study-for-isolated-skin-vasculitis-100281139","NCT02939573","A Randomized Multicenter Study for Isolated Skin Vasculitis","ARAMIS","Inclusion Criteria:\n\n1. Patients with primary skin vasculitis, not associated with any significant extra-cutaneous involvement that would require specific immunosuppressive therapy. Eligible patients will have a diagnosis of either:\n\n   * Isolated cutaneous small vessel (SV) or medium-sized vessel (MV) vasculitis or cutaneous polyarteritis nodosa (PAN)\n   * IgA vasculitis (IgA, formerly Henoch-Schönlein purpura), without active and\u002For progressing renal involvement (stable glomerular filtration rate (GFR) \\>60 ml\u002Fmin; absence of, or mild-and-stable microscopic hematuria without red blood cell casts; absence of, or mild-and-stable proteinuria (\\\u003C1g\u002F24 hours); not requiring systemic immunosuppressive therapy).\n\n   These conditions, when skin-limited, are all currently treated in similar manners in practice. Mild arthralgias, myalgias, peripheral limb edema, fatigue, weight loss ≤6 lbs or 3 kg within past 3 months, low-grade fever, and mild anemia (Hb ≥ 10 g\u002FdL) will be allowed.\n2. The diagnosis of vasculitis must have been confirmed by skin biopsy prior to enrollment (earlier, at diagnosis, and\u002For just prior to enrollment) that has included an immunofluorescence study (in the case of small vessel vasculitis).\n3. Patients must have active cutaneous vasculitis lasting for at least 1 month continuously and\u002For have had 2 or more flares over the six months preceding enrollment (post-inflammatory lesions such as hyperpigmentation or healing ulceration(s) are not to be considered active vasculitis).\n4. Patients must have active \u002F ongoing cutaneous vasculitis lesions at the time of enrollment (post-inflammatory lesions such as hyperpigmentation or healing ulceration(s) are not to be considered active vasculitis).\n5. Patients may have a contra-indication to one of the study drug or have been treated prior to enrollment with one of the study medications but failed to respond to it (according to the study definitions of failure and if they have been on the drug at the target dose or higher for 3 months or longer) or had to stop it because of an adverse event. Such patients can be enrolled directly in the second stage of the study and be randomized to receive one of the two other study drugs. The number of such patients enrolled directly in stage 2 will be capped at 10 (10% of the total recruitment target).\n6. Patients may have received systemic glucocorticoids for their cutaneous vasculitis before enrollment. For the patients on prednisone at the time of enrollment, prednisone should be stopped within a maximum of 6 weeks after enrollment and initiation of the study drug, following a pre-defined tapering schedule. Patients on long-term, low and stable dose of glucocorticoids (≤5 mg\u002Fday prednisone-equivalent) for other conditions (e.g., asthma or adrenal insufficiency) can be enrolled if the likelihood of requiring a dose increase for this other condition is low during the 6 month study period (these patients will remain on that low and stable dose during the study period, with the option to receive one short course of prednisone at higher doses for skin vasculitis flare during the first 3 months of the study period, like any other patients enrolled).\n7. Participant age 18 years or greater.\n\nExclusion Criteria:\n\n1. Presence of significant extra-cutaneous manifestations suggestive of a systemic vasculitis or more diffuse condition. The presence of mild arthralgias, myalgias, peripheral limb edema, fatigue, weight loss ≤6 lbs or 3 kg within past 3 months, low-grade fever, and mild anemia \\[Hb ≥ 10 g\u002FdL\\] are not exclusion criteria. Mild and stable microscopic hematuria without RBC casts and\u002For mild and stable proteinuria (\\\u003C1g\u002F24 hours) are not exclusion criteria. These latter patients must not require systemic immunosuppressive therapy because of possible renal involvement and their GFR must be \\>60 ml\u002Fmin.\n2. Known systemic and\u002For non-skin-isolated vasculitis, such as granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, cryoglobulinemic vasculitis, systemic polyarteritis nodosa, central nervous system vasculitis and patients with detectable antineutrophil cytoplasmic antibody (ANCA) by immunofluorescence or ELISA.\n3. Hypocomplementemic urticarial vasculitis, cryoglobulinemic vasculitis, and other known secondary skin vasculitides such as those secondary to systemic lupus erythematosus, Sjögren syndrome, another auto-immune condition, a cancer, a hematological disorder, an ongoing active infection, or an ongoing medication. Investigators should consider such underlying diagnoses and perform and interpret appropriate laboratory work-up where indicated based on clinical presentation.\n4. History of significant intolerance, allergy or serious adverse events to any of the study medications: such patients can be enrolled directly in the second stage of the study and be randomized to receive one of the two other study drugs. The number of patients enrolled directly in stage 2 of the study will be capped at 10 (10%).\n5. Patients who have contra-indications to two or three of the study drugs (azathioprine, colchicine, or dapsone), or have been treated prior to enrollment with two or three of the study drugs but failed to respond to them, or had to stop two or three of them because of adverse events.\n6. Deficit in glucose-6-phosphate dehydrogenase (G6PD) or history of hemolytic anemia (all patients must be tested for G6PD at the screening visit to assess for their eligibility): such patients can be enrolled directly in the second stage of the study and be randomized to receive one of the two other study drugs (azathioprine or colchicine). The number of patients enrolled directly in stage 2 of the study will be capped at 10 (10%).\n7. Low or absent thiopurine methyltransferase (TPMT) activity (if known, not a requirement for study entry): Patients known to have low or absent TPMT can be enrolled directly in the second stage of the study and be randomized to receive one of the two other study drugs (dapsone or colchicine).\n8. Evidence of significant hepatic insufficiency or liver function tests \\> 2 times the upper limit of normal.\n9. Evidence of significant renal insufficiency or creatinine clearance \\\u003C 60 mL\u002Fmin.\n10. Evidence of significant or symptomatic anemia or Hb \\\u003C 10 g\u002FdL.\n11. Comorbid condition that has moderate or high likelihood of requiring intermittent courses of prednisone within the study period, according to the investigator (e.g. chronic obstructive pulmonary disease (COPD), unstable or severe asthma).\n12. Active cancer or history of malignancy within the previous 5 years (patient in remission of a cancer \\>5 years, or with non-metastatic prostate cancer or treated basal or squamous cell carcinoma of the skin can be enrolled).\n13. Active uncontrolled or serious infection that may compromise or contra-indicate the use of the study medications.\n14. Patient unable to consent.\n15. Pregnant or lactating women.",{"count":129,"type":23},90,[67],"Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.",[133,134,135,136],"Primary Cutaneous Vasculitis","Cutaneous Polyarteritis Nodosa","IgA Vasculitis","Henoch-Schönlein Purpura",{"date":46,"type":47},{"date":139,"type":47},"2017-01-01",{"date":141,"type":23},"2028-12-31",{"name":53,"class":54},16,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100603151","understanding-the-effects-of-pulmonary-arterial-hypertension-on-lean-muscle-mass-100603151","NCT07132788","Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass","MUSCLE UP-PH","Inclusion Criteria:\n\n* Signed informed consent prior to initiation of any study mandated procedure.\n* Diagnosis of PAH belonging to one of the following subgroups of Group 1 PH according to the updated clinical classification \\[Humbert 2022\\]\n\n  * Idiopathic (IPAH)\n  * Heritable (HPAH)\n  * Drugs or toxins induced\n  * Associated (APAH) with one of the following:\n\n    * Connective tissue disease;\n    * Human immunodeficiency virus (HIV) infection;\n    * Congenital heart disease; or\n    * Portopulmonary hypertension\n* Diagnosis of PAH within 6 months of enrollment or diagnosis of PAH and on stable therapy for 3 months prior to enrollment\n* Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC), prior to enrollment showing:\n\n  * mPAP \\> 20 mmHg; and\n  * PAWP or LVEDP ≤ 15 mmHg\n  * PVR \\> 2 Wood units\n\nExclusion Criteria:\n\n* Prior to enrollment, evidence of moderately severe obstructive ventilator defect with:\n\n  * FEV1\u002FFVC ≤ 5th percentile; and\n  * FEV1 z-score \\\u003C 2.5\n* Prior to enrollment, evidence of severe restrictive defect with\n\n  * TLC \\\u003C 5th percentile\n  * FEV1 z-score \\\u003C 4\n* Prior to enrollment, hospitalization (within 1 week) for decompensated right heart failure\n* More than moderate aortic or mitral valve disease\n* LVEF \\\u003C 40% within 1 year of screening\n* Pregnancy",{"count":152,"type":23},150,"OBSERVATIONAL","Patients with pulmonary arterial hypertension (PAH) are at increased risk of muscle loss and decreased physical activity. This study will aim to (1) understand the way in which muscle loss occurs in PAH, particularly the role of fat surrounding the heart, and (2) look at the impact muscle loss has on quality of life, daily physical activity, and hospitalizations in patients with PAH. The findings from this study could help identify potentially treatable factors that may improve the overall quality of life and physical functioning of patients with PAH.\n\nSubjects will be asked to attend a baseline visit where the following will be performed:\n\n* Measure your vital signs\n* Undergo a research blood draw, less than 4 tablespoons\n* Provide a urine pregnancy test (if applicable)\n* Review demographics, personal history, and medical history\n* Review current PAH medications\n* Complete questionnaires on how your PAH affects you\n* Complete a test of physical performance\n* Complete a grip strength test\n* Undergo an echocardiogram (Echo)\n* Complete a six-minute walk test\n* Undergo a Chest CT Scan\n* Undergo a scan of your body composition (DXA scan)\n* Obtain a weight and body composition measurement on the InBody Scale Subjects will also complete activity moniotring, two 24-hour diet recalls, and participate in remote follow-up visits every 6 months",[156],"Pulmonary Hypertension",[158,159],"pulmonary hypertension","body composition","2026-08-17",{"date":162,"type":47},"2026-08-19",{"date":164,"type":47},"2025-05-01",{"date":166,"type":23},"2029-07-01",{"name":53,"class":54},2,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100589167","remote-sputum-collection-in-cystic-fibrosis-100589167","NCT06950892","Remote Sputum Collection in Cystic Fibrosis","Remote Sputum Collection in Adults With Cystic Fibrosis","RESCUe","Inclusion Criteria:\n\n* People with a diagnosis of cystic fibrosis (CF) based on CF Foundation (CFF) guidelines. The CFF guidelines consider a diagnosis of CF based on: (1) two known disease-causing CFTR mutations (based on historical genetic testing in clinical documentation or PortCF, the CFF patient registry), OR (2) sweat chloride 60 mmol\u002FL (based on historical sweat chloride testing in clinical documentation or PortCF) and phenotypic findings consistent with cystic fibrosis in more than one organ system, OR (3) CFF accredited center physician diagnosis, based on clinical manifestations in the absence of two CFTR mutations with full gene mapping (based on historical genetic testing in clinical documentation or PortCF).\n* Age 18 years old or greater\n* People with the ability to comply with study visits and study procedures as judged by the investigator.\n\nExclusion Criteria:\n\n* Solid organ transplant recipients, given the presence of immunosuppression.\n* Those who are unable to tolerate sputum induction (hypertonic saline) or the inability to attempt sputum expectoration.\n* Subjects who do not have access to a FedEx location or pick-up services will be excluded.",{"count":152,"type":23},"Elexacaftor\u002FTezacaftor\u002FIvacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting sputum samples at home and sending them by mail may be feasible, uncertainty remains about how the collection of samples outside of clinic and delays in testing while in the mail impact infection detection. This study will compare bacterial cultures using sputum samples collected at home versus samples collected in clinic (saline-induced sputum and throat swab). This study seeks to shed light on how valuable home collected samples can be and help us better understand the usefulness of home-collected sputum samples for both clinical and research purposes.",[180,181],"Cystic Fibrosis","Infections",[180,183],"Pseudomonas aeruginosa",{"date":162,"type":47},{"date":186,"type":47},"2025-01-15",{"date":188,"type":23},"2028-06-30",{"name":53,"class":54},4,{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":24,"phases":199,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":55},"100585634","phase-2-intra-arterial-tenecteplase-to-improve-the-microvascular-hemodynamics-after-mechanical-thrombectomy-100585634","NCT06904911","Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy","INTIMA-MT","Inclusion Criteria:\n\n* Patient\u002Flegally authorized representative has signed the Informed Consent Form\n* At least 18 years of age\n* Ability to comply with the study protocol, in the investigator's judgment\n* Acute ischemic stroke attributed to anterior circulation large vessel occlusion (of the internal carotid artery or first segment of the middle cerebral artery based on CTA, MRA, or catheter angiogram) being treated with mechanical thrombectomy\n* NIHSS ≥ 6 at the initiation of endovascular therapy (arterial puncture)\n* Time from stroke onset to IA-TNK administration \\\u003C 24 hours. Stroke onset is defined as the time the patient was last known to be at their neurologic baseline\n* ASPECTS ≥ 6 on pre-MT CT imaging\n* If treated \\> 6 hours from stroke onset, CTP imaging must demonstrates favorable mismatch profile (based on RAPID processing: infarct core \\\u003C70 mL, mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 mL)\n* Qualifying neuroimaging (CT and CTP, if applicable) must be obtained \\\u003C120 minutes prior to arterial puncture.\n\nExclusion Criteria:\n\n* Current participation in another investigational drug or device study\n* Known hypersensitivity or allergy to any ingredients of tenecteplase\n* Active internal bleeding\n* Known bleeding diathesis (Alzheimer's patients taking lecanemab)\n* Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \\> 1.7\n* Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)\n* Treatment with a thrombolytic within the last 3 months prior to randomization, inclusive of intravenous thrombolysis during the index stroke.\n* Baseline platelet count \\\u003C 100,000\u002Fmicroliter (results must be available prior to treatment)\n* Baseline blood glucose \\> 400 mg\u002FdL (22.20 mmol\u002FL)\n* Baseline blood glucose \\\u003C 50 mg\u002FdL needs to be normalized prior to randomization\n* Intracranial or intraspinal surgery or trauma within 2 months\n* Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months\n* History of acute ischemic stroke in the last 90 days\n* History of hemorrhagic stroke\n* Presumed septic embolus; suspicion of bacterial endocarditis\n* Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed\n* Pregnant\n* Systolic BP \\>185 mmHg or diastolic BP \\>110 mmHg, refractory to treatment\n* Suspicion of aortic dissection\n* Known allergy to iodine or iodinated contrast\n* Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram\n* Renal failure as defined by a serum creatinine \\> 3.0 mg\u002Fdl or GFR \\\u003C 30\n* Known intracranial neoplasm\n* GI bleeding within the past 21 days\n* Pre-existing medical or neurological disease that will confound the neurological or functional evaluations\n* Premorbid (prior to the index stroke) modified Rankin Scale (mRS) score ≥ 3\n\nAdditional neuroimaging exclusion criteria:\n\n* ASPECTS \\\u003C6 on pre-MT CT imaging\n* Acute intracranial hemorrhage or contrast extravasation on CT before or immediately after MT (prior to study drug administration)\n* Significant mass effect with midline shift on non-contrast CT before or immediately after MT\n* Cervical or intracranial stent placement during endovascular therapy\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA, MRA, or catheter angiography",{"count":22,"type":23},[67],"This is a prospective, single-arm, open-label study to evaluate the efficacy of intra-arterial tenecteplase in improving microvascular reperfusion following successful large vessel recanalization. Acute ischemic stroke patients with large anterior circulation large vessel occlusion will receive a single weight-based dose of intra-arterial tenecteplase after achieving successful large vessel recanalization (defined as TICI ≥ 2b) via standard of care mechanical thrombectomy. Microvascular flow will be assessed by quantitative angiography before and after the intra-arterial drug administration in order to quantify the impact of targeted thrombolysis on microvascular reperfusion. Reperfusion will be secondarily assessed with 24-hour imaging, final infarct volume will be quantified 72 hours following treatment, and functional outcome will be assessed in the short-term by the NIHSS and in the long-term by the 90-day modified Rankin Scale.",[202],"Acute Ischemic Stroke From Large Vessel Occlusion",[204,205,206,207,208,209],"acute ischemic stroke","ischemic stroke","large vessel occlusion","reperfusion","adjuvant thrombolysis","intra-arterial thrombolysis",{"date":44,"type":47},{"date":212,"type":47},"2026-02-13",{"date":214,"type":23},"2026-12-30",{"name":53,"class":54},{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":24,"phases":225,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":55},"100652368","validation-of-the-vision-trainer-clinical-decision-support-software-100652368","NCT07773753","Validation of the Vision Trainer Clinical Decision-Support Software","Validation of the Vision Trainer Clinical Decision-Support Software:A Randomized Comparison of Software-Guided Subjective Refraction(JCC and Non-JCC Algorithms) Against Unassisted Manual Refraction","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form prior to any study procedures.\n* Age ≥18 years at the time of informed consent.\n* Best corrected visual acuity (BCVA) of at least 20\u002F40 in both eyes, measured with current spectacle or contact lens correction.\n* Able to provide informed consent in English.\n* Willing and able to complete an approximately 25-30-minute study visit\n* No significant ocular pathology or media opacity that would preclude accurate standard refraction.\n\nExclusion Criteria:\n\n* Ocular pathology significantly affecting visual function: untreated or advanced glaucoma, advanced age-related macular degeneration, proliferative diabetic retinopathy with vision loss, current retinal detachment, or other posterior segment disease materially impairing BCVA.\n* Recent ocular surgery within the prior 6 months, including refractive surgery (LASIK, PRK, SMILE, phakic IOL), cataract surgery, or other intraocular procedures.\n* Spherical equivalent refractive error exceeding ±12 Diopters.\n* Any medical condition or circumstance that, in the judgment of the Investigator, would preclude safe or valid participation.",{"count":224,"type":23},128,[226],"NA","This study is a prospective, randomized, crossover clinical investigation designed to evaluate the accuracy, efficiency, and usability of the Vision Trainer software for subjective refraction. The study compares software-guided refraction, implemented using both Jackson Cross Cylinder (JCC) and Non-JCC workflows, against standard unassisted manual refraction performed by trained examiners",[229],"Myopia","2026-08-16",{"date":162,"type":47},{"date":233,"type":23},"2026-08",{"date":235,"type":23},"2030-09",{"name":53,"class":54},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":17,"sex":18,"minAge":245,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":24,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":55},"100611859","streamlining-telehealth-for-expanded-prep-utilization-through-community-partnerships-100611859","NCT07246057","Streamlining Telehealth for Expanded PrEP Utilization Through Community Partnerships","Streamlining Telehealth for Expanded PrEP Utilization Through Community Partnerships (STEP-UP)","STEP-UP","Inclusion -\n\nClient Interviews:\n\n1. At least 18 years of age or older\n2. Have received services or participated in programming at a partner CBO in the past 12 months\n3. Currently live in the Philadelphia metropolitan area\n4. Able to provide informed consent\n\nStaff Interviews:\n\n1. At least 18 years of age or older\n2. Currently employed at Philadelphia telePrEP Program or a partner CBO\n3. Serve in a client-facing role (e.g., outreach specialists) or leadership position (e.g., program coordinators) at one of the aforementioned organizations\n4. Have been in their current role for at least 6 months\n5. Able to provide informed consent\n\nClient Surveys:\n\n1. At least 16 years of age or older\n2. Have engaged with a Community TelePrEP Navigator through a partner site CBO to schedule a telehealth appointment with a PrEP provider\n3. Currently live in the Philadelphia metropolitan area\n4. Able to provide informed consent\n\nExclusion-\n\n1. Under 16 years of age (clients surveys) or under 18 years of age (staff interviews or client interviews)\n2. Do not currently live in the Philadelphia metropolitan area\n3. Unable to provide informed consent due to cognitive impairment or other factors\n4. Individuals who pose a safety risk to research staff or other participants\n5. Clients currently living with HIV","16 Years",{"count":247,"type":23},92,[226],"The goal of this study is to learn if STEP-UP (Streamlining Telehealth for Expanded PrEP Utilization through community Partnerships) works to expand access to PrEP for people who could benefit from HIV prevention tools. STEP-UP is an innovative model for PrEP delivery that positions community-based organizations (CBOs) as hubs for PrEP access. STEP-UP builds on the established trust, community expertise, and comprehensive services of CBOs serving individuals who could benefit from HIV prevention tools, integrating telehealth PrEP delivery into their existing infrastructure through partnership with a local telehealth PrEP program. By enabling CBOs to offer telePrEP navigation within their array of health and social services, STEP-UP creates accessible, comprehensive care centers that address barriers to PrEP access faced by individuals who could benefit from HIV prevention tools. The main questions it aims to answer are:\n\n1. Is STEP-UP acceptable and feasible to implement in community settings?\n2. Does STEP-UP increase PrEP prescription rates compared to the existing direct-to-consumer telehealth model?\n\nResearchers will compare people who receive telehealth PrEP services through STEP-UP at community-based organizations to those who access telehealth PrEP through the existing direct-to-consumer telehealth model. Some participants will:\n\n1. Complete surveys about their experiences with the program\n2. Participate in an interview to share their perspectives and feedback about the program.",[251],"HIV",[253,254,255,256],"Pre-exposure prophylaxis","Telehealth","Community-based organizations","Implementation science","2026-08-13",{"date":259,"type":47},"2026-08-14",{"date":261,"type":47},"2026-03-26",{"date":263,"type":23},"2028-07-15",{"name":53,"class":54},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":24,"phases":274,"briefSummary":275,"conditions":276,"keywords":287,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":55},"100545064","using-the-ehr-to-advance-genomic-medicine-across-a-diverse-health-system-100545064","NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System","Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosed with one of the study conditions\n\nExclusion Criteria:\n\n* Under 18 years of age\n* not diagnosed with one of the study conditions",{"count":273,"type":23},1000,[226],"Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and\u002For patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.",[277,278,279,280,281,282,283,284,285,286],"Genetic Predisposition","Paraganglioma","Pheochromocytoma","ALS","Parkinson Disease","Polyneuropathies","Frontotemporal Dementia","Alzheimer Disease","Cardiomyopathy Non-ischemic","Thoracic Aortic Aneurysm",[288,289,290],"Genetic testing","Genomic medicine","Electronic health record","2026-08-11",{"date":259,"type":47},{"date":294,"type":47},"2024-06-10",{"date":296,"type":23},"2027-06-30",{"name":53,"class":54},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":24,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":318,"locationsCount":55},"100531723","improving-care-transitions-for-medicaid-insured-individuals-with-co-occurring-serious-mental-illness-100531723","NCT06203509","Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness","An Equity-focused Intervention to Improve Care Transitions for Medicaid Insured Individuals With Co-occurring Chronic Medical Conditions and Serious Mental Illness","THRIVE-SMI","Inclusion Criteria:\n\n* Medicaid insured\n* Residing in the state of Pennsylvania\n* Experienced a hospitalization at study hospital\n* Agrees to home care at partner home care setting.\n\nExclusion Criteria:\n\n* Individuals under age 18",{"count":307,"type":23},267,[226],"This study aims to evaluate the THRIVE clinical pathway at HUP, focusing on supporting Medicaid-insured individuals, including those with serious mental illness, following hospitalization. The study will assess clinician\u002Fadministrator perspectives on the pathway's feasibility, appropriateness, and acceptability and analyze referral patterns and post-discharge outcomes.\n\nThe objectives are:\n\n1. To conduct a qualitative study evaluating the implementation of THRIVE, particularly its adaptation to include patients with serious mental illness.\n2. To examine referral patterns, 30-day readmission rates, and ED utilization for THRIVE participants, comparing them with those receiving standard care.\n\nParticipants will be referred to home care services during hospitalization and seen by a home care nurse within 48 hours post-discharge. A discharging physician or Advanced Practice Provider will oversee care for 30 days or until a primary care or specialist visit. The Care Coordination Team will hold weekly case conferences for 30 days post-discharge to address both health and mental health needs. The study will compare outcomes of Medicaid-insured patients, including those with serious mental illness, to those receiving usual care.",[311],"Care Transitions","2026-08-10",{"date":314,"type":47},"2026-08-12",{"date":316,"type":47},"2024-04-15",{"date":51,"type":23},{"name":53,"class":54},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":18,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":55},"100651750","evaluating-the-preferences-and-tradeoffs-of-ai-based-electronic-consultations-for-older-adults-in-primary-care-100651750","NCT07766694","Evaluating the Preferences and Tradeoffs of AI-based Electronic Consultations for Older Adults in Primary Care","Evaluating the Safety and Appropriateness of AI-based E-Consults for Older Adults in Primary Care","PATIENTS:\n\nInclusion Criteria:\n\n* Adult, 65 years of age or older\n* Had at least two office visits at Penn Medicine in the past 12 months\n* Has an upcoming appointment in a Penn Medicine primary care setting, including family medicine, internal medicine, and geriatric medicine\n\nExclusion Criteria:\n\n* Documented Alzheimer's, dementia, or related condition\n\nCLINICIANS:\n\nInclusion Criteria:\n\n* Adult, 18 years of age or older\n* Works at Penn Medicine as one of the following: physician, nurse practitioner, or physician's assistant\n* Works in a primary care Penn Medicine setting including: family medicine, internal medicine, geriatrics medicine\n\nExclusion Criteria:\n\n* Actively in medical school, internship, or residency","65 Years",{"count":328,"type":23},220,[226],"Electronic consultations, or e-consults, let a primary care doctor request medical advice from a specialist without requiring the patient to attend a separate visit. Artificial intelligence (AI) systems may be able to provide this type of advice, potentially making e-consults faster and less costly. However, whether AI-based e-consults are acceptable may depend on how patients and clinicians weigh factors such as who provides the advice, how quickly it is received, its cost, and its quality.\n\nThe purpose of this study is to examine how older adult patients and primary care clinicians weigh these factors when comparing e-consults produced by a human specialist with those produced by an AI system. In the study, participants will complete a one-time survey in which they compare sets of two hypothetical e-consults. Each e-consult will include a different combination of features, such as whether the advice comes from a human or AI, the expected wait time, the cost, and the quality of the advice. This study will estimate how much patients and clinicians value each feature in an e-consult. The findings will inform the potential future AI e-consults, so they better reflect patient and clinician preferences.",[332,333],"Primary Care Patients","Primary Care Provider","2026-08-09",{"date":259,"type":47},{"date":233,"type":23},{"date":338,"type":23},"2026-12",{"name":53,"class":54},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":24,"phases":348,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100650711","designing-and-evaluating-multi-level-implementation-strategies-to-address-alcohol-use-within-oncology-care-100650711","NCT07752576","Designing and Evaluating Multi-level Implementation Strategies to Address Alcohol Use Within Oncology Care","Inclusion Criteria:\n\n* Over age 18 and diagnosed with cancer\n* Receiving care at one of our pilot study sites\n\nExclusion Criteria:\n\n* None",{"count":347,"type":23},265,[226],"To assess the potential effects of our multi-level implementation strategies for increasing SBIRT for alcohol use among cancer patients and to refine our methods, the investigators are conducting a pilot-trial with 4 clinics and will be doing interviews with patients and clinicians. The investigators will use a pragmatic, randomized clinical trial design, with 2 clinics randomized to our multi-level implementation strategies and 2 clinics randomized to usual care (prescreening assessment of alcohol use and patient information about alcohol use). Clinicians will include physicians as well as nurses and nurse practitioners who complete patient visits. Patients will include those diagnosed with cancer who have completed the alcohol use prescreening at a visit within the previous 30 days; the investigators will not deliver implementation strategies until at least 7 days following the initial prescreening given the informatics need to deliver messages to eligible patients at the point of care. Patients in the usual care arm will receive the prescreening and information about alcohol use and cancer outcomes and who to contact for further assessment integrated into their \"After Visit Summary\"; clinicians in the usual care sites will receive information about alcohol as a determinant of cancer outcomes and who to contact for referrals for screening at the outset of the pilot trial. Each patient who completes the subsequent clinic visit where the patient and clinician directed nudges are delivered (in the multi-level intervention arm) or not (usual care) will be tracked for 6 months to determine if SBIRT for alcohol use was completed (the primary outcome variable). Lastly, 10 patients and 10 clinicians will be invited to complete key informant interviews to provide feedback about their experiences with the implementation strategies.",[351,352],"Alcohol Misuse Treatment","Alcohol Misuse",[354,355,352,356],"Implementation Reserach","Implementation Science","Behavioral Economics","2026-08-07",{"date":314,"type":47},{"date":360,"type":23},"2027-10-01",{"date":362,"type":23},"2028-08-31",{"name":53,"class":54},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":24,"phases":373,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":55},"100627624","cd45be-hspc--cart-45-cells-100627624","NCT07451054","CD45BE-HSPC + CART-45 Cells","Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n1\\. Signed informed consent form 2. Male or females age ≥ 18 years 3. Disease-Specific Criteria\n\na. B-cell Non-Hodgkin Lymphoma (B-cell NHL)- including the following sub-types:\n\ni. Patients with any of the following large B-cell lymphoma diagnoses who meet the prior treatment criteria outlined below: Diffuse Large B-cell Lymphoma not otherwise specified (DLBCL NOS); Primary Cutaneous DLBCL; Primary Mediastinal (thymic) Large B-cell Lymphoma; ALK+ Anaplastic Large B-cell Lymphoma; High-Grade B-cell Lymphoma with MYC and BCL2 and\u002For BCL6 rearrangements (i.e., \"Double or Triple Hit\"); High-grade B-cell Lymphoma, NOS; T-cell Rich B-cell Lymphoma; Transformed Follicular Lymphoma; or any aggressive B-cell lymphoma arising from indolent lymphoma.\n\n1\\. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND 2. Relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy.\n\nii. Follicular Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy (not including a single agent monoclonal antibody therapy).\n\niii. Mantle Cell Lymphoma\n\n1. Patients must have either failed\u002Frelapsed after, or be ineligible for, prior commercial CAR T cell therapy; AND\n2. Relapsed\u002Frefractory disease after at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   iv. Marginal Zone Lymphoma- relapsed\u002Frefractory disease after at least 2 prior lines of appropriate therapy, including a Bruton tyrosine kinase (TKI) inhibitor. Note: Single-agent monoclonal antibody therapy does not count towards prior lines of therapy.\n\n   b. T-cell Non-Hodgkin Lymphoma (T-cell NHL)\n\n   i. Histologically or cytologically confirmed relapsed or refractory (r\u002Fr) mature aggressive T- and NK-cell neoplasms as defined in the 5th edition of the WHO Classification of Hematolymphoid tumors, which includes any of the following diagnoses:\n\n   • Peripheral T-cell Lymphoma, NOS (PTCL-NOS);\n\n   • Nodal T-cell Lymphomas with T Follicular Helper \\[TFH\\] Phenotype, including Follicular T cell Lymphoma, Angioimmunoblastic Lymphoma, or Anaplastic Large Cell Lymphoma (ALCL);\n\n   • ALK+ or ALK-, Enteropathy-Associated T-cell Lymphoma (EATL);\n\n   • Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL);\n\n   • Extranodal NK\u002FT-cell Lymphoma;\n\n   • Primary Cutaneous T-cell Lymphoma (CTCL);\n\n   • Transformed Mycosis Fungoides (tMF) without blood involvement;\n\n   • Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma;\n\n   • Subcutaneous Panniculitis-like T-cell Lymphoma.\n\n   ii. Must have received at least one prior line of systemic therapy for their lymphoma. Additional prior treatment provisions required for the following indications:\n\n1\\. Participants with Anaplastic Large Cell Lymphoma (ALCL) must have received prior Brentuximab vedotin, unless contraindicated.\n\n2\\. Participants with Subcutaneous Panniculitis-like T-cell Lymphoma or Transformed Mycosis Fungoides (tMF) must have received at least 2 prior lines of systemic therapy.\n\nc. Hodgkin Lymphoma (HL)\n\ni. Patients with histologically proven classical Hodgkin Lymphoma that is CD45 positive by IHC or flow cytometry by a CLIA certified laboratory; AND\n\nii. Relapsed\u002Frefractory disease after at least 2 prior lines of therapy which must include the following:\n\n1. Brentuximab vedotin and immune checkpoint inhibitors (unless contraindicated); AND\n2. Autologous stem cell transplant (unless patient has chemorefractory disease to salvage treatment) d. Large Cell Transformation of CLL (Richter's Transformation) i. Patients must be primary refractory or received at least 1 prior line of treatment for Richter's Transformation.\n\n4\\. Patients are appropriate candidates for autologous HSCT as per physician-investigator clinical discretion\n\n5\\. Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:\n\na. Have no active GVHD and require no immunosuppression\n\nb. Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility\n\n6\\. Adequate organ function defined as:\n\n1. Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance ≥ 35 mL\u002Fmin and not on dialysis\n2. ALT\u002FAST ≤ 3 x ULN\n3. Direct bilirubin ≤ 2.0 mg\u002Fdl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg\u002Fdl\n4. Left Ventricular Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO\u002FMUGA\n5. DLCO \\> 45% predicted value; adjusted for level of hemoglobin\n6. Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air 7. ECOG Performance Status 0-1\n\nExclusion Criteria:\n\n1. Active hepatitis B or hepatitis C infection\n2. Any active, uncontrolled infection.\n3. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification.\n4. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n5. Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study.\n6. Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n7. Active acute or chronic GVHD requiring systemic therapy.\n8. Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications.\n9. Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs\u002Fsymptoms of CNS involvement.\n10. Patients with evidence of a circulating T-cell malignancy as measured by flow cytometry.\n11. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).\n12. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n13. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods.",{"count":372,"type":23},42,[374],"PHASE1","This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as \"CART-45 cells\") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as \"CD45BE-HSPC\") in patients with relapsed or refractory hematologic malignancies.",[377,378,379,380],"B-Cell Non-Hodgkin Lymphoma (NHL)","Richter's Transformation","T-Cell Non-Hodgkin Lymphoma","Hodgkin Lymphoma",{"date":312,"type":47},{"date":383,"type":47},"2026-08-05",{"date":385,"type":23},"2051-07",{"name":53,"class":54},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":89,"enrollmentInfo":394,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":55},"100624910","effect-of-ctbs-on-startle-and-tms-evoked-bold-100624910","NCT07415772","Effect of cTBS on Startle and TMS-evoked BOLD","The Effect of Right dlPFC cTBS on Acute Measures of Anxiety, Functional Connectivity, and TMS-evoked BOLD Responses.","Inclusion Criteria:\n\n* Able to give their consent\n* Right-handed\n* Individuals receiving therapy for anxiety must be stable on their regimen for at least 4 weeks prior to study enrollment.\n\nExclusion Criteria:\n\n* Non-english speaking\n* Any significant medical or neurological problems\n* Current or past non-anxiety-related psychiatric comorbidity, active or history of active suicidal ideation\n* Alcohol\u002Fdrug problems in the past year or lifetime alcohol or drug dependence\n* Medications that act on the central nervous system\n* History of seizure\n* History of epilepsy\n* Increased risk of seizure for any reason\n* Pregnancy, or positive pregnancy test\n* Any medical condition that increases risk for fMRI or TMS\n* Any metal in their body which would make having an MRI scan unsafe\n* Any sort of medical implants\n* Hearing loss\n* Claustrophobia\n* orthostatic hypotension",{"count":395,"type":23},140,[226],"The right dorsolateral prefrontal cortex (dlPFC) is increasingly being targeted with transcranial magnetic stimulation (TMS) to reduce anxiety expression; however, there is little mechanistic evidence supporting an optimized treatment protocol. Thus, the objective of the current project is to develop an interleaved TMS\u002FfMRI that can assess the effect of neuromodulatory (potentially therapeutic) TMS protocols on neural and behavioral measures related to anxiety expression. PUBLIC HEALTH RELEVANCE: These results will yield direct evidence that 1 Hz and cTBS modulate brain activity associated with anxiety expression and regulation, thus informing novel TMS based anxiety treatments.",[399],"Anxiety",[401,402],"anxiety","transcranial magnetic stimulation",{"date":312,"type":47},{"date":405,"type":23},"2026-09-01",{"date":407,"type":23},"2031-06-30",{"name":53,"class":54},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":415,"minAge":4,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":418,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":55},"100650959","implementation-of-a-disparities-in-labor-outcomes-dashboard-100650959","NCT07756424","Implementation of a Disparities in Labor Outcomes Dashboard","Inclusion criteria:\n\n* full term (greater than or equal to 37 weeks gestation)\n* singleton gestations\n* intact membranes\n* undergoing an induction of labor requiring cervical ripening\n\nExclusion criteria:\n\n\\- prior cesarean","FEMALE",{"count":417,"type":23},2300,[226],"This proposal will determine if a Disparities in Labor Outcomes dashboard can be used as an implementation strategy to increase compliance to an evidence-based set of interventions for labor induction in a two-site difference-in-differences study design.",[421,422],"Labor Induction","Cesarean Birth",[424,425,426],"labor induction","cesarean birth","maternal morbidity","2026-08-06",{"date":312,"type":47},{"date":430,"type":23},"2026-10",{"date":432,"type":23},"2027-07",{"name":53,"class":54},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":24,"phases":443,"briefSummary":444,"conditions":445,"keywords":450,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":168},"100645787","de-restrict-deimplementing-activity-restriction-for-preterm-birth-prevention-100645787","NCT07698483","DE-RESTRICT: Deimplementing Activity Restriction for Preterm Birth Prevention","Deimplementation of Activity Restriction for Preterm Birth Prevention in High-Risk Pregnancy (DE-RESTRICT): A Pilot Single-Arm Hybrid Effectiveness-Deimplementation Trial","Inclusion Criteria:\n\n* For Providers: Physicians, midwives, physician assistants, nurse practitioners, nurses, nursing assistants, medical assistants, and other healthcare staff who provide or participate in prenatal or high-risk pregnancy care or consultation at a participating site.\n* For Patients: Secondary patient-reported outcomes draw on pregnant individuals at high risk for preterm birth (qualifying diagnoses include short cervix, cervical insufficiency, multiple gestation, preterm labor, preterm contractions, vaginal bleeding, placental conditions, or a history of prior preterm birth), between 0 and 12 weeks postpartum for the survey measures. The activity restriction recommendation measure is collected through the Take Home Electronic Assessment (THEA) and therefore reaches only patients enrolled in THEA, at 33 weeks of gestation, across all periods; in the pre-deimplementation and post-deimplementation periods the additional survey battery is sent only to patients with a qualifying high-risk diagnosis.\n\nExclusion Criteria:\n\n* For Providers: Staff who self-exclude by choosing not to interact with deimplementation meetings and communications\n* For Patients: Patients are excluded if they are unable to walk or are hospitalized without discharge home before delivery after the qualifying diagnosis is made.",{"count":442,"type":23},237,[226],"DE-RESTRICT is a pilot study testing whether a strategy to reduce the use of activity restriction and bedrest in pregnancy is acceptable, appropriate, and feasible for prenatal care providers, and whether it changes how often activity restriction is recommended. Activity restriction and bedrest are commonly advised to try to prevent preterm birth, but they do not prevent it and may cause harm, and national guidelines recommend against them. The study takes place at two prenatal care settings within one health system and unfolds across four periods. In the pre-deimplementation period the study team develops a local clinical guideline and measures baseline outcomes. In the run-in period most provider education is delivered through interactive sessions with feedback, and audit and feedback begins. In the maintenance period audit and feedback continues. In the post-deimplementation period audit and feedback continues and outcomes are measured again. The study measures provider acceptability, appropriateness, and feasibility, the rate of activity restriction recommendations, patient-reported wellbeing and care experience, and the preterm birth rate.",[446,447,448,449],"Preterm Birth","Activity Restriction","Bed Rest","Low-Value Care",[451,452,453,454,455,456,457,458],"deimplementation","low-value care","activity restriction","bedrest","preterm birth","audit and feedback","implementation science","hybrid trial",{"date":312,"type":47},{"date":461,"type":47},"2026-07-16",{"date":463,"type":23},"2027-08-31",{"name":53,"class":54},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":483,"leadSponsor":485,"locationsCount":55},"100639729","phase-1-tcr1188-abc-cells-in-kras-mutated-cancers-100639729","NCT07594067","TCR1188-ABC Cells in KRAS-mutated Cancers","Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)","Inclusion Criteria:\n\n1. Patients ≥ 18 years of age\n2. Patients with one of the following diagnoses:\n\n   1. Histologically confirmed metastatic pancreatic adenocarcinoma or cholangiocarcinoma\n   2. Histologically confirmed metastatic colorectal cancer\n   3. Histologically confirmed metastatic non-small cell lung cancer\n3. HLA-A\\*11:01 positive as confirmed by a CLIA certified laboratory.\n4. KRAS G12V mutation positive disease as confirmed on tissue, blood, or plasma by next generation sequencing by a CLIA certified laboratory.\n5. Received prior treatment for their primary malignancy as follows:\n\n   1. Pancreatic Cancer\u002FCholangiocarcinoma Patients: At least one prior line of standard of care therapy for advanced stage disease. For pancreatic cancer patients, this must include a gemcitabine or fluorouracil (5 FU)-based regimen.\n   2. Colorectal Cancer Patients: At least three prior lines of standard of care therapy for advanced stage disease. Prior treatment must include all of the following unless the patient was ineligible for a specific therapy type: i). a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimen, ii). an anti-vascular endothelial growth factor (VEGF) agent, and iii). regorafenib, trifluridine-tipiracil, or fruquintinib. Patients with microsatellite instability-high (MSI-H) disease must also have received, or be ineligible for, prior treatment with an immune checkpoint inhibitor.\n   3. Non-Small Cell Lung Cancer Patients: At least one prior line of standard of care therapy for advanced stage disease.\n6. Evidence of radiographically detectable disease within 8 weeks of physician-investigator confirmation of eligibility.\n7. Adequate organ function within 4 weeks of eligibility confirmation by a physician-investigator defined as:\n\n   1. Serum creatinine ≤ 1.5 mg\u002Fdl or creatinine clearance ≥ 50 cc\u002Fmin per the Cockcroft-Gault Equation; Patient must not be on dialysis.\n   2. ALT\u002FAST ≤ 5 x ULN (patients with liver metastases) or ALT\u002FAST ≤ 2.5 x ULN (patients without liver metastases)\n   3. Total bilirubin ≤ 1.5 mg\u002FdL x ULN, unless the subject has Gilbert's syndrome (if so, direct bilirubin must be ≤ 2.0 mg\u002FdL x ULN)\n   4. Left Ventricle Ejection Fraction (LVEF) ≥ 50% confirmed by ECHO\u002FMUGA\n   5. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \\> 92% on room air\n8. Patients must have adequate hematologic reserve within 4 weeks of eligibility confirmation by a physician-investigator and must not be dependent on transfusions to maintain these hematologic parameters. Adequate hematologic reserve is defined as:\n\n   1. Hemoglobin ≥ 8 g\u002FdL\n   2. Absolute neutrophil count ≥ 1000\u002FμL\n   3. Platelet count ≥ 100,000\u002FμL\n9. ECOG Performance Status that is either 0 or 1.\n10. Signed, written informed consent\n\nExclusion Criteria:\n\n1. Active hepatitis B or hepatitis C infection\n2. Patients with a severe acquired or inherited immunodeficiency, including HIV positive patients with a CD4 count ≤ 350 cells\u002FμL. In order to qualify, HIV positive patients must also be on an established antiretroviral therapy regimen with a viral load of \\\u003C400 copies\u002FmL.\n3. Any other active, uncontrolled infection.\n4. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification (see Appendix 5).\n5. Severe, active co-morbidity that in the opinion of the physician-investigator would preclude participation in the study.\n6. Active invasive cancer, other than the proposed cancer included in the study, within 2 years prior to eligibility confirmation by a physician-investigator. \\[Note: non-invasive cancers treated with curative intent (e.g., non-melanoma skin cancer) may still be eligible\\].\n7. Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3.\n8. Patients requiring chronic treatment with systemic steroids or immunosuppressant medications. Low-dose physiologic replacement therapy with corticosteroids equivalent to prednisone 10 mg\u002Fday or lower, topical steroids and inhaled steroids are acceptable. For additional details regarding use of steroid and immunosuppressant medications, please see Section 5.6.\n9. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg daily of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.\n10. Patients with unstable angina, serious uncontrolled cardiac arrhythmia, and\u002For myocardial infarction within 6 months of physician-investigator confirmation of eligibility.\n11. Prior history of myocarditis.\n12. Patients with pneumonitis\u002Finterstitial lung disease requiring steroid treatment.\n13. Patients with active\u002Funtreated brain metastases. \\[Note: History of treated metastases may still be eligible.\\]\n14. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) or tocilizumab.",{"count":473,"type":23},30,[374],"This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.",[477,478,479,480],"Cholangiocarcinoma","Colorectal Cancer","Non-Small Cell Lung Cancer","Pancreatic Adenocarcinoma",{"date":427,"type":47},{"date":233,"type":23},{"date":484,"type":23},"2042-07",{"name":53,"class":54},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":17,"sex":18,"minAge":493,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":24,"phases":497,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":508,"locationsCount":55},"100615506","neurobehavioral-changes-following-spaceflight-stressors-100615506","NCT07293494","Neurobehavioral Changes Following Spaceflight Stressors","NeuroSTAR","Inclusion Criteria:\n\n* Age between 21-60 years.\n* Free of psychological, psychiatric or physical conditions that preclude participation.\n* BMI between 18.5 and 35.\n* Self-reported regular sleep schedule; able to maintain their sleep schedule during the course of the study.\n* Self-reported sleep duration of 6-8.5 h per night (verified by daily logs).\n* Ability to read\u002Fwrite English.\n* Able to stand unassisted for up to 10 minutes at a time and able to lift arms above head.\n\nExclusion Criteria:\n\n* Alcohol or drug abuse in the past year based upon history and urine toxicology screen.\n* Potential alcohol abuse or heavy drinking in the past year, based on self-report (AUDIT-C Q2 score above 1 or Q3 score above 2).\n* Alcohol-naive based on self-report (AUDIT-C Q1 score of 0).\n* Allergies, conditions or circumstances that preclude alcohol consumption, including use of medication or supplements (prescription or over the counter) that could interfere with study participation or make it hazardous for a subject to partake (e.g., anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified), or for which alcohol consumption should be limited or avoided (e.g. items identified on NIAAA's 'Harmful Interactions' list).\n* Cultural or personal beliefs that preclude alcohol consumption.\n* Body Mass Index ≤18.5 or ≥ 35.\n* Current smoker\u002Ftobacco user or using nicotine replacement therapy. Those that have been nicotine-free for ≥ 30 days may be included.\n* Excessive caffeine consumption (\\> 650mg\u002Fday combining all caffeinated drinks regularly consumed during the day).\n* Acute, chronic, or debilitating medical conditions, major Axis I psychiatric illness based on history, physical exam, blood and urine chemistries; or self-reported history of neurological, psychiatric, or other medical condition that precludes participation, such as nervous system disorders, dementia, chronic migraines, or epilepsy; panic, bipolar or schizoaffective disorder; sleep disorders including insomnia, narcolepsy and obstructive sleep apnea; liver, kidney or heart disease, hypertension; infectious diseases; diabetes; or any other conditions for which medical monitoring is advised and which may require medications and\u002For lifestyles that preclude alcohol consumption and\u002For sleep disruption.\n* Current depression as determined on the Beck Depression Inventory (Beck, 1996), by either a total score of 19 or higher or a response greater than 0 on Q9 (suicidality).\n* Cardiovascular, gastrointestinal, or musculoskeletal problems, or other major conditions such as organ failure, cancer or patients requiring oxygen.\n* Prior history or diagnosis of any sleep disorder including Obstructive Sleep Apnea (AHI ≥15 events\u002Fhour) - from ambulatory or in lab polysomnography; Restless legs syndrome or periodic limb movement disorder; Insomnia; Parasomnia; High Risk of OSA based on STOP-BANG Questionnaire (\"yes\" on at least 4 of 8 questions); High Risk of Restless Legs Syndrome (RLS) based on Cambridge-Hopkins Screening questionnaire; High Risk of Insomnia based on Insomnia Severity Index (score of 22 or higher).\n* Current use or use within the past month of a prescription or over-the-counter sleep medication or stimulant (based on self-report or review with a study clinician).\n* History of potential MRI contraindications, including: tinnitus; sensorineural hearing loss \\> 30 dB; pace maker or internal defibrillator; metallic implants (e.g. orthopedic plates after bone fractures, joint replacements, surgical staples or clips, artificial heart valves, stents, cava filters); metallic splinters (e.g. after an accident or due to war injury); non-removable dental brace; Tattoo (some tattoo inks contain metallic particles); permanent make-up; non-MRI compatible intrauterine contraceptive device; cochlear implant (implanted hearing device); medication pump; acupuncture needle; other foreign bodies\u002Fobjects which are non-removable; pregnancy (or its possibility); previous brain and\u002For heart surgery.\n* History of severe motion sickness, based on self-report or driving simulator response.\n* Pregnant or currently breast feeding. People that menstruate will have a pregnancy test performed via urine sample during screening, as those that are currently pregnant are unable to participate in the study.\n* Individuals who self-report severe contact dermatitis or allergy to bandages, silicone, nickel or silver.\n* Currently working night, swing, split or rotating shift.\n* Planned travel across more than one time zone within 7 days of the scheduled study start date.\n* Habitual daytime napping.","21 Years","60 Years",{"count":496,"type":23},56,[226],"This study aims to investigate the impairing effects of known central nervous system (CNS) stressors in a controlled environment in order to predict and mitigate analogous risks in spaceflight. Up to 56 healthy individuals aged 25-60 will spend approx. 110 hours in a laboratory, where they will be exposed to 27 hours of sleep deprivation and will consume alcohol to reach a BAC of 0.08 on a separate day. They will perform cognitive and sensorimotor tasks and undergo MRIs and blood draws.",[500,501,502,503],"Stressor, Individual","Alcohol Impairment","Sleep Deprivation","Impairment, Cognitive",{"date":427,"type":47},{"date":506,"type":23},"2026-08-04",{"date":118,"type":23},{"name":53,"class":54},{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":517,"targetDuration":518,"studyType":153,"phases":4,"briefSummary":519,"conditions":520,"keywords":526,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":55},"100437150","resuscitative-tee-collaborative-registry-100437150","NCT04972526","Resuscitative TEE Collaborative Registry","Evaluation of the Clinical Impact and Safety of Focused Transesophageal Echocardiography During Resuscitation of Critically Ill Patients in the Emergency Department and Intensive Care Settings","rTEECoRe","Inclusion Criteria:\n\n* Adult critically-ill patients who as part of their routine clinical care receive focused TEE in the emergency department of intensive care setting.\n\nExclusion Criteria:\n\n* Children (age under 18 years)\n* Vulnerable populations",{"count":273,"type":23},"1 Month","The general objective of this study is to evaluate the clinical impact and safety of focused, point-of-care transesophageal echocardiography (TEE) used during the evaluation of critically-ill patients in the emergency and intensive care settings. The target population for this study are critically-ill patients over the age of 18 who as part of their routine clinical care are receiving a focused TEE.\n\nThe primary objective of this study is to determine the clinical impact and safety of TEE performed during the evaluation of critically-ill patients in the emergency department and intensive care settings.\n\nThe secondary objective(s) of this study are to characterize the use of this imaging modality in the subsets of critically-ill patients in shock and cardiac arrest; including but not limited to; description of the frequency of studies, clinical indications, clinician characteristics, echocardiography findings, timing of studies, procedure-related complications and patient outcomes.",[521,522,523,524,525],"Cardiac Arrest","Cardiac Arrest Circulatory","Cardiac Arrest, Out-Of-Hospital","Shock","Hemodynamic Instability",[527,528,521,529,530],"Transesophageal Echocardiography","Resuscitation","Point-of-care Ultrasound","Focused Cardiac Ultrasound",{"date":312,"type":47},{"date":533,"type":47},"2020-12-01",{"date":535,"type":23},"2027-12-15",{"name":53,"class":54},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":89,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":546,"briefSummary":547,"conditions":548,"keywords":550,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":4},"100636401","effect-of-aitbs-on-intrinsic-spectral-dynamics-and-task-performance-100636401","NCT07565207","Effect of aiTBS on Intrinsic Spectral Dynamics and Task Performance","The Effect of Within-network aiTBS on Cortical Excitability, Intrinsic Oscillatory Bands, and Behavioral Task Performance","Inclusion Criteria:\n\n* Able to give their consent\n* Right-handed or ambidextrous\n\nExclusion Criteria:\n\n* Non-english speaking\n* Current or past non-anxiety-related psychiatric comorbidity.\n* Active or history of active suicidal ideation\n* Alcohol\u002Fdrug problems in the past year or lifetime alcohol or drug dependence\n* Medications that act on the central nervous system\n* History of seizure\n* History of epilepsy\n* Increased risk of seizure for any reason\n* Pregnancy, or positive pregnancy test\n* Any medical (e.g., stroke, breathing problems, motion disorders) or neurological (e.g., a significant brain injury or brain infection history that increases seizure risk) condition that increases risk for fMRI or TMS (Protocol will follow recommendations from Rossi et al. 2021 doi:10.1016\u002Fj.clinph.2020.10.003)\n* Any metal in their body which would make having an MRI scan unsafe\n* Any sort of medical implants\n* Hearing loss\n* Claustrophobia\n* orthostatic hypotension",{"count":545,"type":23},80,[226],"Aim 1: Measure local shifts in cortical spectral dynamics following aiTBS. Aim 2: Measure network-specific shifts in task performance following aiTBS. Exploratory aim: Evaluate changes to resting state spectral dynamics in absence of stimulation after aiTBS.",[549],"Brain Plasticity",[402,551],"electroencephalography",{"date":383,"type":47},{"date":554,"type":23},"2026-10-01",{"date":556,"type":23},"2030-05-30",{"name":53,"class":54},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":89,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":567,"briefSummary":568,"conditions":569,"keywords":570,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":573,"leadSponsor":574,"locationsCount":4},"100636400","arousal-related-memory-following-theta-burst-stimulation-100636400","NCT07565194","Arousal-related Memory Following Theta Burst Stimulation.","Arousal-related Memory of Movie Clips During Individualized IPS Targeting fMRI and TBS.","Inclusion Criteria:\n\n* Able to provide informed consent\n* Right-handed (to ensure consistency in motor threshold determination)\n\nExclusion Criteria:\n\n* Non-English speaking\n* Significant medical problems\n* Current or past psychiatric disorder\n* Active or history of suicidal ideation\n* Alcohol or drug problems in the past year, or lifetime alcohol or drug dependence\n* Medications affecting the central nervous system\n* History of seizure, epilepsy, or other neurological problems\n* Any increased risk for seizure\n* Pregnancy\n* Medical conditions that increase risk for fMRI or TMS\n* Metal in the body that makes MRI unsafe\n* Medical implants\n* Claustrophobia\n* Orthostatic hypotension",{"count":566,"type":23},120,[226],"Aim 1: Active cTBS to IPS will disrupt arousal-dependent temporal memory, reflected in reduced relative order discrimination accuracy and expanded temporal distance estimates, relative to sham.\n\nAim 2: Active iTBS to IPS will enhance arousal-dependent temporal memory, reflected in improved relative order discrimination accuracy and compressed temporal distance estimates, relative to sham.\n\nAim 3: Baseline physiological arousal, trait anxiety (STAI), Beck Anxiety Inventory (BAI), trauma symptoms (PCL-5), and individualized E-field strength will predict the magnitude of TBS-induced behavioral changes in temporal memory.",[399],[401,402],{"date":383,"type":47},{"date":554,"type":23},{"date":556,"type":23},{"name":53,"class":54},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":62,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":24,"phases":584,"briefSummary":585,"conditions":586,"keywords":588,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":591,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":55},"100620331","partial-enteral-nutrition-as-therapeutic-augmentation-of-advanced-pharmacological-therapy-in-patients-with-active-crohns-disease-100620331","NCT07356232","Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease","PANDORA","Inclusion Criteria:\n\n1. Ability to provide informed consent\n2. A confirmed diagnosis of Crohn's disease\n3. Plan to start one advanced Crohn's Disease therapy (anti-TNF, anti-IL12\u002FIL23, anti-IL23, anti-alpha 4 beta 7, JAK inhibitor).\n4. If taking aminosalyilates, methotrexate or thiopurines, participant must be on a stable does for at least 8 weeks prior to screening. Methotrexate, aminosalicylates and thiopurines are permitted to be continued with the advanced therapy if on stable dose for at least 8 weeks. Methotrexate or thiopurines may be initiated within 1 week of starting the advanced pharmacologic therapy\n5. Active disease defined by at least one of the criteria from group A AND one from group B.\n\nGroup A\n\n1. Short Crohn's Disease Activity Index (sCDAI) score \\>175, and if taking corticosteroids, dose cannot exceed 30 mg for prednisone or 9 mg for budesonide,\n2. sCDAI \\\u003C 175 and on 10- 30 mg of prednisone (or 6-9 mg of budesonide) at a stable dose for 2 weeks. Must have experienced worsening of symptoms with attempts to taper to a lower dose of steroids in 3 months prior to screening.\n\nGroup B\n\n1. Fecal calprotectin at baseline ≥ 300 ug\u002Fgr\n2. Active disease seen at colonoscopy within 8 weeks of the screening visit. Active disease requires presence of mucosal breaks including either diffuse scattered erosions or at least one ulcer (\\>5mm diameter)\n3. Active disease on cross-sectional imaging (CT scan, MRI or ultrasound) within 8 weeks of the screening visit (evidence of acute inflammation, such as ulceration or bowel wall thickening with restricted diffusion)\n\nExclusion Criteria:\n\n1. Pregnancy or breast feeding\n2. Presence of an ostomy\n3. Previous total colectomy\n4. Short gut syndrome from prior surgeries\n5. Consuming parenteral nutrition for more than 350 calories per day in the two weeks prior to screening\n6. Having been on the Crohn's Disease Exclusion Diet (CDED) in the 2 weeks prior to screening\n7. Plan to receive two simultaneously administered advanced therapies\n8. Planning to start a new medication in the same class as the medication currently taking. This does not include a switch from Ustekinumab to anti-IL23 drugs.\n9. Impending need for CD surgery per investigator\n10. Symptomatic stricture or stricture inducing bowel dilation (\\>3cm) as per local investigator.\n11. \\>4 very soft or liquid bowel movements per day when feeling well\n12. Diabetes mellitus requiring therapy with medication\n13. Known allergy to any ingredient in the Kate Farms formula.\n14. Unable to complete online surveys\n15. Unable to receive shipments of PEN formula.\n16. Starting a new medication for Crohn's disease other than steroids in the 8 weeks prior to the screening visit\n17. Has not consumed food in the last 6 days prior to screening\n18. Starting an accelerated (non-FDA approved) dose of advanced therapy\n19. At time of screening, participant is taking both Prednisone and Budesonide\n20. Untreated C. difficile infection with the last 8 weeks","80 Years",{"count":545,"type":23},[226],"This is a multicenter non-randomized prospective open label trial of partial enteral nutrition (PEN) among patients with active Crohn's disease (CD) starting standard of care advanced therapy. Our central hypothesis is that combination therapy of PEN and pharmacologic therapy is more efficacious than pharmacologic therapy alone and can be well-tolerated for patients. Participants will choose to either include PEN along with starting their advanced therapy or will choose not to include PEN. 80 participants will be recruited from 15 sites across the United States.",[587],"Crohn's Disease, Active",[589,590],"partial enteral nutrition","Crohn's disease exclusion diet",{"date":383,"type":47},{"date":593,"type":23},"2026-09",{"date":595,"type":23},"2029-04",{"name":53,"class":54},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":24,"phases":606,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":55},"100642449","early-phase-1-18f-ftha-imaging-of-the-intestinal-and-central-lymphatic-system-100642449","NCT07645573","18F-FTHA IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","INVESTIGATION OF A POSITRON-EMITTING LONG-CHAIN FATTY ACID (18F-FTHA), FOR IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM","FTHA","Inclusion Criteria:\n\nInclusion Criteria (Healthy Volunteer Cohort)\n\n1. Male and female participants will be ≥ 18 years of age.\n2. \"Healthy Volunteer\" is defined for the purposes of this study as a volunteer who is in good general health in the opinion of an investigator (some well controlled chronic medical conditions may be allowed at the discretion of an investigator if they do not believe they will interfere with the collection of imaging data, specific excluded medical conditions are listed under exclusion criteria).\n3. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nInclusion (Patient with suspected TD-venous junction obstruction cohort)\n\n1. Male and female participants will be ≥ 18 years of age\n2. Informed of the investigational nature of this study and able to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n3. Patient with chronic abdominal pain, ascites protein losing enteropathy, as well edema, with clinically suspected obstruction of the TD-venous junction and who are candidates for TD-venous junction plasty and or TD-Venous bypass\n\nExclusion Criteria:\n\nExclusion Criteria that apply to Healthy Volunteers only\n\n1. Currently taking medication for cardiac disease, hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, and\u002For history of cardiac surgery per medical record review and\u002For self-report\n2. Known history of liver or kidney disease per medical record review and\u002For self-report\n\nExclusion Criteria that applies to Healthy Volunteers and Patients:\n\n1. Women who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential on the day of each of the PET\u002FCT scans.\n2. Subjects who report claustrophobia or Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Self-reported difficulty with swallowing pills or allergy to components of Ensure Plus\n4. Patients with a history of medical illness or disorder that in the opinion of an investigator and\u002For study physician could compromise patient safety or interfere with the collection of imaging data, or ability to complete the study and procedures, will be excluded.\n\nParticipant may not be involved in any other research studies involving ionizing radiation conducted within 1 year of their participation of this study.",{"count":7,"type":23},[607],"EARLY_PHASE1","The project will be performed over a period of approximately two years. In the first year the \\[18F\\]FTHA tracer will be developed, optimized, and tested on normal volunteers. During the second year, the tracer will be investigated on patients with suspected obstruction of the thoracic duct (TD).",[610],"Lymphatic Obstruction",[612],"thoracic duct","2026-08-03",{"date":427,"type":47},{"date":616,"type":47},"2025-10-10",{"date":618,"type":23},"2029-06-30",{"name":53,"class":54},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":17,"sex":18,"minAge":493,"maxAge":89,"enrollmentInfo":626,"targetDuration":4,"studyType":24,"phases":627,"briefSummary":628,"conditions":629,"keywords":635,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":637,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":55},"100640797","effects-of-ketogenic-diet-on-alcohol-intoxication-100640797","NCT07602270","Effects of Ketogenic Diet on Alcohol Intoxication","Inclusion Criteria:\n\n1. Age 21 years to 50 years old.\n2. Willingness to provide signed, informed consent and commit to completing study procedures. Reported on at least one day in the month prior to consent of consuming 2 or more standard alcohol drinks on a single day.\n\nExclusion Criteria:\n\n1. Unwilling or unable to refrain from use, within 24 hours of the alcohol lab procedures, psychoactive medications or medication that may affect study results.\n2. Current DSM-5 diagnosis of any major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.\n3. Currently taking medication(s) that could interfere with study participation or make it hazardous for the subject to participate. (e.g. anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified)\n4. Positive urine drug screen, positive for all substances but marijuana at screening or study visits (may be repeated once and if the result is negative on repeat, it is not exclusionary).\n5. A current, clinically significant physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement, administration of ketogenic diet, or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam).\n6. Currently suffering from or has a history of stroke and\u002For stroke related spasticity.\n7. Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture, inter-cranial bleeding or abnormal MRI (self-report, medical history).\n8. Weight greater than 225lbs (Need to cap amount of alcohol given based on weight to individuals).\n9. Females who are pregnant or breast-feeding\n10. Contraindication to MRI, including presence of ferromagnetic objects, claustrophobia or fear of enclosed, medical conditions that prevent subjects from lying comfortably flat on his\u002F her back for up to 2 hrs.",{"count":22,"type":23},[226],"The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol. Participants will be asked to undergo \\~4 weeks of ketogenic diet intervention. The study involves three lab visits: Lab 1 before starting the diet, Lab 2 after about 2 weeks after starting the diet, and Lab 3 after being on the diet for 4 weeks. All of the labs will include an alcohol tolerance test, and blood draws. Lab 1 and Lab 3 will also include an Magnetic resonance imaging scan. Due to scheduling, study procedures at 2 and 4 weeks may occur +\u002F- 3 days. Magnetic resonance imaging (MRI) of the brain will measure levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA. Alcohol tolerance will be tested using a dose of alcohol (approximately 4-5 alcohol beverages) to will elevate breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol. Blood samples will be collected to measure varying metabolites.",[630,631,632,633,634],"Ketogenic Diet","Alcohol Drinking","Alcohol Use Disorder","Magnetic Resonance Imaging","Alcohol Intoxication",[630,636],"Alcohol tolerance test",{"date":506,"type":47},{"date":639,"type":47},"2026-05-14",{"date":641,"type":23},"2030-05-01",{"name":53,"class":54},""]